Dr. Changchun Deng presented at American Society of Hematology (ASH) Annual Conference

December 01, 2017

Dr. Deng (Principal Investigator and lead author) and colleagues presented their latest research on “Umbralisib/TGR-1202 as a Novel Dual PI3K/CK1 Inhibitor Has a Unique Therapeutic Role in Silencing Oncogenes in Aggressive Lymphomas”.

 

https://ash.confex.com/ash/2017/webprogram/Paper106213.html